HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities.
Chu W, Xu H, Wang Y, Xie Y, Chen YL, Tan X, Huang C, Wang G, Wang Q, Luo W, Xia N, Geng M, Xie Z, Wang C.
Chu W, et al. Among authors: xu h.
Clin Transl Med. 2022 Apr;12(4):e791. doi: 10.1002/ctm2.791.
Clin Transl Med. 2022.
PMID: 35384333
Free PMC article.
No abstract available.